Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MRKNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$83.14-0.1%$86.53$75.93▼$134.63$209.66B0.4312.00 million shs11.75 million shsSMMTSummit Therapeutics$27.90+13.1%$21.36$2.10▼$36.91$20.58B-0.463.84 million shs7.35 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.0.00%+0.37%+2.03%-16.68%-34.80%SMMTSummit Therapeutics0.00%+18.88%+60.71%+39.64%+535.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRKMerck & Co., Inc.5 of 5 stars4.33.05.03.94.03.33.8SMMTSummit Therapeutics2.8534 of 5 stars4.51.00.00.03.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKMerck & Co., Inc. 2.59Moderate Buy$111.1333.66% UpsideSMMTSummit Therapeutics 3.00Buy$37.4034.05% UpsideCurrent Analyst Ratings BreakdownLatest SMMT and MRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.004/28/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.00 ➝ $40.004/25/2025SMMTSummit TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$31.00 ➝ $44.004/23/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/22/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$85.004/17/2025MRKMerck & Co., Inc.GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.00 ➝ $115.003/26/2025SMMTSummit TherapeuticsSummit RedstoneSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$35.003/26/2025SMMTSummit TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$23.00 ➝ $35.003/21/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/12/2025SMMTSummit TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.00(Data available from 5/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKMerck & Co., Inc.$63.92B3.28$2.88 per share28.82$14.85 per share5.60SMMTSummit Therapeutics$700K29,401.82N/AN/A$0.11 per share253.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKMerck & Co., Inc.$17.12B$6.8712.358.400.7726.67%45.35%17.36%N/ASMMTSummit Therapeutics-$614.93M-$0.31N/AN/AN/AN/A-85.42%-52.66%N/ALatest SMMT and MRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A4/24/2025Q1 2025MRKMerck & Co., Inc.$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billion2/24/2025Q4 2024SMMTSummit Therapeutics-$0.08-$0.08N/A-$0.08N/A$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRKMerck & Co., Inc.$3.243.90%+5.73%47.16%14 YearsSMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKMerck & Co., Inc.0.791.361.15SMMTSummit TherapeuticsN/A8.318.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKMerck & Co., Inc.76.07%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipMRKMerck & Co., Inc.0.09%SMMTSummit Therapeutics88.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRKMerck & Co., Inc.69,0002.52 billion2.53 billionOptionableSMMTSummit Therapeutics110737.68 million86.28 millionOptionableSMMT and MRK HeadlinesRecent News About These CompaniesTower Research Capital LLC TRC Raises Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)May 5 at 4:04 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Price Target Raised to $41.00May 5 at 3:01 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Trading 16.9% Higher After Better-Than-Expected EarningsMay 4 at 10:50 AM | marketbeat.comWhy Summit Therapeutics Inc. (SMMT) Soared Last WeekMay 4 at 7:21 AM | insidermonkey.com250,000 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Acquired by Boxer Capital Management LLCMay 4 at 6:25 AM | marketbeat.comSusquehanna Fundamental Investments LLC Makes New $1.20 Million Investment in Summit Therapeutics Inc. (NASDAQ:SMMT)May 4 at 4:35 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 16.9% Following Better-Than-Expected EarningsMay 4 at 1:43 AM | americanbankingnews.comQ2 EPS Forecast for Summit Therapeutics Reduced by AnalystMay 3 at 7:12 AM | marketbeat.comHC Wainwright Analysts Lower Earnings Estimates for SMMTMay 3 at 2:05 AM | americanbankingnews.comThis Soaring Stock Just Delivered More Good News. Time to Buy?May 2 at 6:29 PM | finance.yahoo.comSummit Therapeutics Q1 Loss Narrower Than Expected, Sales NilMay 2 at 10:05 AM | zacks.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call TranscriptMay 2 at 8:56 AM | insidermonkey.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025May 1, 2025 | businesswire.comSummit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past MonthApril 30, 2025 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) Sees Unusually-High Trading Volume - What's Next?April 30, 2025 | marketbeat.comJMP Securities Reiterates "Market Outperform" Rating for Summit Therapeutics (NASDAQ:SMMT)April 30, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Has $117 Million Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)April 30, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Summit Therapeutics (NASDAQ:SMMT)April 29, 2025 | americanbankingnews.comWhy Is Summit Therapeutics Stock Trading Higher On Monday?April 28, 2025 | benzinga.comThree Seasons Wealth LLC Acquires New Position in Summit Therapeutics Inc. (NASDAQ:SMMT)April 28, 2025 | marketbeat.comBarclays PLC Has $5.89 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)April 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMMT and MRK Company DescriptionsMerck & Co., Inc. NYSE:MRK$83.14 -0.12 (-0.14%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$83.10 -0.05 (-0.05%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Summit Therapeutics NASDAQ:SMMT$27.90 +3.23 (+13.09%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$27.86 -0.04 (-0.14%) As of 05:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Why Energy Stocks Like Exxon and Hess Are Back in Focus Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Western Digital: Is the Storage Sector Set for a Rebound? Wingstop Stock Jumps on Q1 Beat, Expansion Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
